Metformin is used as a first-line therapy for type 2 diabetes (T2D) and prescribed for
numerous other diseases. However, its mechanism of action in the liver has yet to be …

Aims: To conduct the first GWAS of metformin response, in order to identify genetic
predictors of metformin efficacy in humans and identify potential metformin molecular …

Purpose Metformin is widely used to treat type 2 diabetes mellitus (T2DM) individuals.
Clinically, inter-individual variability of metformin response is of significant concern and is …

Metformin, a biguanide agent, is the first-line treatment for type 2 diabetes mellitus due to its
glucose-lowering effect. Despite its wide application in the treatment of multiple health …

One‐third of type 2 diabetes patients do not respond to metformin. Genetic variants in
metformin transporters have been extensively studied as a likely contributor to this high …

Metformin is the first-line antidiabetic drug with over 100 million users worldwide, yet its
mechanism of action remains unclear. Here the Metformin Genetics (MetGen) Consortium …

Metformin is the front-line treatment for type 2 diabetes worldwide. It acts via effects on
glucose and lipid metabolism in metabolic tissues, leading to enhanced insulin sensitivity …

Metformin is currently considered as a promising anticancer agent in addition to its anti-
diabetic effect. To better individualize metformin therapy and explore novel molecular …

Pharmacogenomics is the study of the contribution of inheritance to variation in drug
response—variation that can range from a loss of the desired therapeutic effect at one end of …

OBJECTIVE Metformin is the most common treatment for type 2 diabetes (T2D). However,
there have been no pharmacogenomic studies for T2D in which a population of color was …